Adamas Pharmaceuticals (NASDAQ:ADMS) – Investment analysts at William Blair dropped their Q1 2018 earnings per share estimates for shares of Adamas Pharmaceuticals in a research report issued to clients and investors on Monday, April 16th. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings of ($1.51) per share for the quarter, down from their prior forecast of ($1.50). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Adamas Pharmaceuticals’ FY2018 earnings at ($6.57) EPS.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.84 million. During the same quarter in the prior year, the company posted ($0.68) EPS. The firm’s quarterly revenue was up 1435.1% on a year-over-year basis.
A number of other equities research analysts have also recently weighed in on ADMS. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Wednesday, January 3rd. Mizuho restated a “buy” rating and set a $48.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, January 23rd. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, January 25th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Noble Financial restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Friday, February 23rd. Two research analysts have rated the stock with a sell rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $42.89.
Shares of NASDAQ ADMS opened at $25.85 on Wednesday. Adamas Pharmaceuticals has a fifty-two week low of $13.50 and a fifty-two week high of $44.00. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. The stock has a market cap of $653.29, a P/E ratio of -6.51 and a beta of 1.59.
In related news, CEO Gregory T. Went sold 4,541 shares of Adamas Pharmaceuticals stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total transaction of $116,930.75. Following the transaction, the chief executive officer now directly owns 182,610 shares of the company’s stock, valued at $4,702,207.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Rajiv Patni sold 1,252 shares of Adamas Pharmaceuticals stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total value of $32,476.88. Following the transaction, the insider now directly owns 21,515 shares in the company, valued at $558,099.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,360 shares of company stock worth $164,138. 29.00% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of ADMS. SG Americas Securities LLC purchased a new position in Adamas Pharmaceuticals in the 3rd quarter worth about $110,000. Granite Springs Asset Management LLC purchased a new position in Adamas Pharmaceuticals in the 4th quarter worth about $207,000. MetLife Investment Advisors LLC purchased a new position in Adamas Pharmaceuticals in the 4th quarter worth about $239,000. Prosight Management LP purchased a new position in Adamas Pharmaceuticals in the 4th quarter worth about $407,000. Finally, Hartwell J M Limited Partnership increased its stake in Adamas Pharmaceuticals by 65.0% in the 4th quarter. Hartwell J M Limited Partnership now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $559,000 after purchasing an additional 6,500 shares in the last quarter. 77.33% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/04/19/q1-2018-earnings-estimate-for-adamas-pharmaceuticals-issued-by-william-blair-adms.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.